PubMed Health⌕ Search

Biomedical subjects

D G Braun

Publications and source records attributed to D G Braun.

At least 19 recordsLinked to original sources
PubMed1997

Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation.

Suppression of Epstein-Barr virus (EBV) lymphoproliferation by three commercial human immunoglobulin (hu-Ig) preparations, one enriched with immunoglobulin A (hu-IgA-IgG) and the other two containing more than 97% immunoglobulin G (hu-IgG) with anti-EBV antibodies was studied. All three human preparations suppress EBV-induced lymphoproliferation in vitro and reduce release of interleukin (IL)-6 and IL-10 dose-dependently, irrespective, however, of the titer of EBV-specific antibodies present. This result was unexpected. Human Ig also reduces human recombinant IL-6-induced lymphoproliferation in EBV-free cultures and augments low-dose human recombinant IL-10-provoked suppression. In vivo studies used mice with severe combined immunodeficiency (SCID), reconstituted with human tonsillar mononuclear cells, and then infected with EBV from B95-8-derived supernatants. Immediate injection of hu-Ig after EBV infection, if given only once, delayed, and if given every two or four weeks, abolished the induction of EBV-associated lymphomas. Delay of hu-Ig injection by 48 hours after infection was less effective. Hu-IgG was consistently more efficacious than hu-IgA-IgG. Under these conditions the best survival rates were obtained with sustained hu-IgG administrations every two weeks. Serum hu-IL-6 and hu-IL-10 were detectable only in lymphoma-bearing SCID mice. Hu-Ig treatment reduced the detectability of both cytokines. These results suggest that hu-Ig-with antibodies to EBV-may exert a beneficial treatment potential for EBV-induced lymphoproliferation in immunocompromised patients. The dependence of this suppressive effect of hu-Ig on specific anti-EBV antibodies in vivo remains to be resolved.

Animals↗
PubMed1995

Quantitative cytofluorimetric determination of cell membrane-associated large tumor antigen on SV40-transformed cells.

The aim of this study was to quantitate the number of cell membrane-located SV40 large tumor antigen (large T) molecules of SV40-transformed cell lines by cytofluorimetric analysis. Five different SV40-transformed cell lines were labelled by either a biotin- or a fluorescein-conjugated monoclonal antibody, PAb1605, which is specific for the large T carboxyterminus. The conjugated-antibody fluorescence signals of the stained large T molecules of transformed cells were measured via cytofluorimetry. Comparison of the fluorescence signals of calibrated beads bearing a known number of fluorescein molecules to the signals of conjugated PAb1605 antibodies bound on microbeads to a defined number of IgG binding sites made it possible to determine the number of antibody-accessible large T molecules per SV40-transformed cell. The numbers (x10(-4)) found per cell were 1.0 (ELONA, hamster), 3.0 (VLM, mouse), 3.5 (mKSA, mouse), 11 (C57SV, mouse), and 5.5 (SV80, human), respectively. Thus, the technique described allows a precise quantitation of surface-exposed, antibody-accessible viral antigen expression.

Animals↗
PubMed1995

Monospecific polyclonal anti-anti-idiotypic antibodies to the carboxyterminal undecapeptide of the SV40 large tumour antigen.

The murine monoclonal antibody PAb1605 defines an epitope, peptide Lys(698)-Thr(708) (KT), on the carboxyterminus of the tumour(T)antigen of SV40-transformed cells. In vivo and in vitro experiments had shown that this sequence represents an epitope for both humoral and cellular immune responses. When injected into rabbits PAb1605 induces anti-idiotypic antibodies (Ab-2). Ab-2 beta (internal image type) was purified by adsorption chromatography and characterized by the ability of KT to compete with the binding of ab-2 with ab-1. Murine anti-anti-idiotypic antibodies (ab-3) were obtained by immunization of mice with ab-2 beta. Both ab-1 and ab-3 JgG showed affinities to immunoprecipitated SV40 T antigen by immunoblot analysis and to nuclear SV40 T antigen by the immunofluorescence assay. The binding of ab-3 to SV40 T antigen was completely inhibited by competition with KT. We conclude that the polyclonal ab-3 is of the ab-3 subtype and specific for only one epitope which is represented by KT and defined by ab-1. The results demonstrate that the specificity for a defined peptide epitope of an antibody was conserved even after two consecutive steps of anti-idiotypic-antibody formation in two host species. Since this postulate of network theory could be verified for a sequence of a tumour-associated antigen which represents a B- and T cell epitope, this model is of great interest for further tumour immunological studies.

Amino Acid Sequence↗
PubMed1994

The cell-binding carboxyterminal undecapeptide of SV40 tumour antigen provides protective cell-dependent immunity.

This paper describes the use of the synthetic carboxyterminal undecapeptide of large SV40 tumour antigen, lys698-thr708 (KT) to protect Balb/c mice against growth of subcutaneously transplanted tumorigenic SV40-transformed cells (VLM). The vaccine was prepared by conjugation of KT with 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide (SPDP). Addition of the SPDP-derivative of KT to syngeneic spleen cells rendered KT covalently linked to free thiol-groups of the cell membranes by the formation of -S-S-CH2-CH2-CO-epsilon-NH-lys698 bonds. Vaccination with KT-conjugated cells was intraperitoneal. Alternatively, KT-conjugated cells were generated in the peritoneum by injection of PDP-KT ((2-pyridyldithio)propionic acid-KT). As a control 60Co-irradiated VLM cells were used. In five experiments all VLM-vaccinated and the majority of the PDP-KT-(or KT-spleen cell)-vaccinated mice were protected against tumour growth. However, mice pretreated with saline, unconjugated spleen cells, free KT, KT conjugated to bovine serum albumin, or KT with incomplete Freund's adjuvant developed tumours. Treatment of PDP-KT-vaccinated mice with anti-CD4 or anti-CD8 immunoglobulin abolished tumour immunity completely. Thus, covalent binding of the carboxyterminal undecapeptide of SV40 tumour antigen to viable, untransformed cells yielded a vaccine which protects Balb/c mice against SV40 tumours.

Adjuvants, Immunologic↗
PubMed1994

A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.

A phase I/IIA clinical trial with the chimeric mouse-human monoclonal antibody CGP 47,439 to the principal neutralization determinant in the V3 region of human immunodeficiency virus type 1 (HIV-1) strain IIIB envelope protein gp120 is reported. The trial was an uncontrolled single-center, open-label, multidose tolerability, immunogenicity, and pharmacokinetic study in homosexual men with advanced HIV disease. Patient groups were formed on the basis of the reactivity of the antibody with the gp120 of their HIV-1 isolates. Intravenous infusions of 1, 10, and 25 mg of antibody were followed by seven escalated doses of 50, 100, and 200 mg, every 3 weeks. The antibody was well tolerated; no toxicity was observed. Some patients showed a transient but insignificant antibody response to the antibody with no apparent adverse reactions or accelerated elimination of it. Substantial serum levels of the antibody were maintained with a mean t1/2 beta of 8-16 days. A virus burden reduction was observed in some patients.

Acquired Immunodeficiency Syndrome↗
PubMed1994

PAb1614, a monoclonal antibody reactive with the tumor antigens of SV40, JC, BK, and polyoma virus, and other JC virus tumor antigen cross-reactive antibodies of the PAb1601-1636 panel.

PAb1614, an SV40-specific monoclonal antibody of the panel PAb1601-1636 reacts with large and small tumor antigens of SV40, BK and JC virus, and with polyoma virus large and middle tumor antigens, but not with the large tumor antigen of the lymphotropic papova virus. Using immunofluorescence and immunoblot competition assays and ELISA with synthetic peptides, it is shown that the epitope is represented by the SV40 tumor antigen undecapeptide, K39-E49. This peptide comprises the tumor antigen consensus sequence, H42-G47, of the polyoma viruses. However, the epitope of PAb1614 probably does not exactly coincide with this hexapeptide. This explains why some cross-reactions are less strong, or absent, as in the case of the lymphotropic papova virus. Further antibodies of the PAb1601-1636 panel that cross-react with the JC virus large tumor antigen are PAb1602, 1604, 1606, 1618, 1621, 1622, 1623, 1624, 1626, 1629, and 1633.

Amino Acid Sequence↗
PubMed1993

hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.

OBJECTIVE: To determine whether passive transfer of a monoclonal antibody specific for the principal neutralizing determinant in the V3 region of HIV-1IIIB gp120 can protect mice with severe combined immunodeficiency (SCID) transplanted with normal human peripheral blood leukocytes (hu-PBL), designated hu-PBL-SCID mice, from subsequent challenge with the homologous viral strain. DESIGN AND METHODS: hu-PBL-SCID mice were given intraperitoneal injections of an anti-HIV-1 neutralizing murine monoclonal antibody (BAT123), its mouse-human chimeric form (CGP 47 439), or a control murine antibody (PNTU), at a dose of 40 mg/kg. The mice were then challenged intraperitoneally with 10 mouse infectious doses of HIV-1IIIB. Three weeks later the mice were killed, and spleen cells and peritoneal lavage collected for determination of infection by coculture for viral isolation and by detection of HIV-1 DNA using polymerase chain reaction (PCR). RESULTS: All three antibodies had similar serum half-lives of 9-12 days. No toxicity was observed in the animals. HIV-1 was recovered by coculture from five out of the six mice given PNTU, and by PCR from two out of the six mice given PNTU, but was not recovered by either technique from any of the 12 mice given BAT123 or CGP 47 439. CONCLUSION: BAT123 and CGP 47 439, which are specific for the principal neutralizing determinant of HIV-1IIIB, protect hu-PBL-SCID mice from infection by this viral strain. Our findings support the use of the hu-PBL-SCID mouse as an in vivo model for studying protection against HIV-1 infection by passive immunization with anti-HIV-1 neutralizing antibodies.

Animals↗
PubMed1991

Structure of cis-1-([4-(1-imidazolylmethyl)cyclohexyl]methyl)imidazole- succinic acid complex.

CGS 14796C, C14H20N4.C4H6O4, Mr = 362.43, monoclinic, C2/c, a = 28.148 (4), b = 9.722 (1), c = 19.200 (2) A, beta = 133.06 (1) degree, V = 3838.88 A3, Z = 8, Dx = 1.26 Mg m-3, lambda (Cu K alpha) = 1.5418 A, mu 0.702 mm-1, F(000) = 1552, T = 294 K, R = 0.075 for all 3285 reflections. The structure is composed of linear chains of alternating CGS 14796C and succinic acid molecules. The CGS 14796C molecule is in an extended conformation.

Aromatase Inhibitors↗
PubMed1991

Structure of (+/-)-aminoglutethimide.

(+/-)-3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione, C13H16N2O2, Mr = 232.3, monoclinic, P2(1)/n, a = 16.895 (2), b = 8.519 (1), c = 8.762 (1) A, beta = 95.71 (1) degree, V = 1254.9 (2) A3, Z = 4, Dx = 1.23 g cm-3, lambda(Mo K alpha) = 0.71069 A, mu = 0.785 cm-1, F(000) = 496, T = 294 K, R = 0.064 for all 3676 reflections. The molecule is L shaped with the p-aminophenyl and the piperidinedione groups forming the vertical arm and the base, respectively. The polar imide half of the piperidinedione group is in front of the L for the active + enantiomer and at the back for the less-active - enantiomer. The structure is very similar to that of phenobarbital. Intermolecular interactions include one strong and one weak hydrogen bond and an apparent interaction between one of the amino H atoms with the pi cloud of the phenyl ring.

Aminoglutethimide↗
PubMed1991

Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine.

A phase 1 trial of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine was done in 25 healthy seronegative subjects. The antigen, env2-3 (SF2), was a nonglycosylated polypeptide representing the gp120 region of the env gene of the HIV-1(SF2) isolate. It was produced in genetically engineered yeast as a denatured molecule incapable of binding CD4. A synthetic lipophilic muramyl tripeptide (MTP-PE) was used as an adjuvant. Ten subjects received adjuvant alone and 15 received 50- or 250-micrograms doses of env2-3 (SF2) administered intramuscularly in two immunization regimens. In general, adjuvant and vaccine were well tolerated. Antibody responses to both the homologous antigen, env2-3 (SF2), and antigens from other highly divergent HIV isolates were elicited in the majority of vaccine recipients. However, antibody titers were low, without neutralizing activity. In 9 of 11 subjects who received the complete vaccine immunization series, a significant specific T lymphocyte response was observed.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1991

Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B.

The crystal and molecular structures of 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile hydrochloride (CGS 16949A) and bis(p-cyanophenyl)imidazo-1-yl methane hemisuccinate (CGS 18320B) have been determined as part of structure-activity relationship studies of non-steroidal aromatase inhibitors. CGS 18320B crystallizes with two inhibitor molecules in the asymmetric unit that are similar in conformation. The cyanophenyl groups and the imidazole moieties in the CGS 18320B molecules display a propellor-like arrangement. The orientation of the imidazole ring in CGS 16949A, which is constrained by the piperidine ring, differs by about 80 degrees from the orientations in both CGS 18320B molecules. The conformations of both compounds are consistent with the proposed model (Banting et al. (1988) J. Enz. Inhibit., 2, 216) for inhibitor binding by positioning of the cyanophenyl group in the steroid A-ring binding site and interaction of the imidazole nitrogen with the iron of the haem.

Aromatase Inhibitors↗
PubMed1990

Reversible inhibition of human placental microsomal aromatase by CGS 18320B and other non-steroidal compounds.

The effect of bis-(p-cyanophenyl)imidazo-1-yl-methane hemisuccinate (CGS 18320B) and other non-steroidal compounds on the aromatization of androstenedione by human placental microsomal aromatase was studied. CGS 18320B exhibited competitive inhibition with an apparent Ki of 0.16 nM, a 90 and 3800-fold increase in affinity compared to 4-hydroxyandrostenedione and amino-glutethimide, respectively. The inhibition is not time-dependent, indicating that the active site interaction is reversible. CGS 18230B showed a two-fold increased affinity as compared to 4-(5,6,7,8-tetrahydroimidazo[1,5a]pyridin-5-yl)benzonitrile (CGS 16949A) and cis-1-[(4-[(1-imidazoyl)methyl]cyclohexyl)methyl]-imidazole succinate (CGS 14796C) which showed Ki values of 0.35 and 0.39 4M, respectively. 1-[2-[1-(4-carboxyphenyl)-3-ureido]ethyl]-2-(4-pyridyl)-2-imidazoline monohydrochloride (CGP 15720A) showed negligible inhibition.

Androstenedione↗
PubMed1990

Immunolabeling of JC virus large T antigen in neonatal hamster brain before tumor formation.

Using immunolabeling methods, the JC virus (JCV) early or regulatory protein, large T antigen, was demonstrated in frozen sections of neonatal hamster brains before tumor formation. Three days after intracerebral inoculation of 2500 hemagglutinating units of JCV, T antigen was expressed predominantly in nuclei of cells in the external granular layer and newly forming internal granular layer of the cerebellum and also in cell nuclei located in the hippocampus, periventricular areas, and the olfactory bulb. At 7 days postinoculation (p.i.), most cerebellar T antigen-containing cells had migrated to the internal granular layer, but by 15 days p.i., cells that expressed T antigen was greatly reduced in number or absent. However, by 30 days p.i., the internal granular layer of the cerebellum again contained T antigen-positive cells. In contrast to the scattered cells seen at 3 or 7 days p.i., these cells appeared in dense clusters thought to represent pretumor foci. Since JCV capsid proteins were not detected at any time, JCV may establish a latent or abortive infection in cells during their mitotic phase and these cells initially express T-antigen during migration or become immunoreactive later before tumor formation.

Animals↗
PubMed1988

Chromogenic labeling of milk oligosaccharides: purification by affinity chromatography and structure determination.

Oligosaccharides from human milk were derivatized with 4'-N,N-dimethylamino-4-amino-azobenzene (DAAB) by reductive amination and purified by affinity chromatography on immobilized antibodies followed by resolution of the retained antigenic molecules by adsorption chromatography on HPLC. The visibility to the naked eye and the favorable handling properties of the DAAB-oligosaccharides (desalting, quantification) offered distinctive advantages over underivatized oligosaccharides. Analysis by MS and NMR identified the two major antigens as the Lewis a active pentasaccharide and the Lewis b active hexasaccharide, respectively. Further derivation of DAAB-oligosaccharides by palmitoylamidoacetaldehyde generated glycolipid-like compounds suitable for immunological detection by in situ overlay techniques after separation by thin-layer chromatography.

Carbohydrate Sequence↗
PubMed1988

Synthetic oligopeptides define epitopes at the amino- and carboxy-terminus of simian virus 40 large tumor antigen which are recognized by monoclonal antibodies.

Synthetic oligopeptides were used to define the epitopes recognized by monoclonal antibodies directed against the SV40 large tumor (T) antigen. The two monoclonal antibodies PAb 1622 and PAb 1626 reacted with the N-terminal undecapeptide Met(1)-Leu(11) as detected by inhibition of nuclear SV40 T antigen immunofluorescence. Antibody PAb 1605 recognized the hexapeptide Thr(701)-Pro(706) at the carboxy-terminus of the SV40 T antigen as detected by inhibition of an enzyme-linked immunosorbent assay. The specificities of these monoclonal antibodies differ from those of antibodies previously raised against the respective synthetic oligopeptides.

Antibodies, Monoclonal↗
PubMed1988

Characterization of a monoclonal antibody against infective larvae of Brugia malayi.

Monoclonal antibodies were produced following immunization of mice with live infective larvae of Brugia malayi. One of these, 46.08.76, is an antibody that promotes adherence of mouse peritoneal macrophages and human peripheral blood leucocytes to the infective larvae of B. malayi and Wuchereria bancrofti, respectively, and kills them. Fresh normal serum, as a source of complement, augments this effect. The same monoclonal antibody conferred 89% protection to jirds (Meriones unguiculatus) against challenge infection of B. malayi stage-three larvae. This monoclonal antibody recognizes antigens of 80,000, 67,000, 52,000 and 36,000 MW proteins present among the antigens of larvae, as detected by an immunoblotting technique. The antibody also reacts with antigens of infective larvae of Litomosoides carinii, Dipetalonema viteae and B. pahangi, but to a smaller extent.

Animals↗